Cleft larynx, posterior

Summary

Cleft larynx, posterior (MONDO:0008990) is a disease. A subtype of laryngotracheoesophageal cleft — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cleft larynx, posterior
Mondo ID	MONDO:0008990
MeSH	C537851
OMIM	215800
Orphanet	2005
UMLS	C1859083
MedGen	349091
GARD	0004015
Is cancer (heuristic)	no

Also known as: cleft larynx, posterior · laryngotracheoesophageal cleft pulmonary hypoplasia · Novak syndrome

Disease family

This is a subtype of laryngotracheoesophageal cleft. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › tracheal disorder › laryngotracheoesophageal cleft › cleft larynx, posterior

Related subtypes (5): laryngotracheoesophageal cleft type 0, laryngotracheoesophageal cleft type 1, laryngotracheoesophageal cleft type 2, laryngotracheoesophageal cleft type 3, laryngotracheoesophageal cleft type 4

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.